Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vitro progresses with stem cell treatment for diabetes
The new advances include a process to induce differentiation of functional beta cells from these stem cells that contain and release insulin in response to elevated glucose levels.
The new advances include a process to induce differentiation of functional beta cells from these stem cells that contain and release insulin in response to elevated glucose levels.
Novelos plans to submit a proposal to the Department of Health and Human Services (DHHS) in 2006 for treatment of patients with NOV-002 after acute exposure to lethal
The increase in R&D expenses for the quarter is due mainly to continued progress in Neurogen’s proprietary clinical program in insomnia and in its preclinical programs for depression
The protein identified allows the bacterial strain known as E coli 0157:H7 to obtain the iron it needs for survival in the body. Iron is a catalyst for
According to the researchers, the “Quaking” gene is likely to suppress tumor growth by inhibiting production of a protein associated with GLI1, a cancer-causing oncogene highly associated with
IBM and Memorial Sloan-Kettering Cancer Center (MSKCC) are building a state-of-the-art integrated information management system to improve the ability of clinicians and researchers to study long-term cancer-related illnesses,
Although medical advances in perinatal care mean many more premature babies are saved each year, those who survive are often at risk of developing bronchopulmonary dysplasia, a chronic
The findings, which showed that participants benefited from the antibiotic rifaximin (Xifaxan) even after the course of treatment ended, support previously published research identifying small intestine bacterial overgrowth
Metabolex and Astellas Pharma initiated a multi-year research and drug discovery collaboration in late March 2002 and extended the agreement for one year in March 2005. Focused on
The safety monitoring board, which includes experts in neurology, cardiology and clinical pharmacology, reviewed the safety data of the first 62 subjects enrolled into the study, and has